Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

July 07, 2015 11:01 PM ET


Company Overview of PNP Therapeutics, Inc.

Company Overview

PNP Therapeutics, Inc., a biopharmaceutical company, develops a platform technology and proprietary products for the treatment of cancer based on the selective expression of E. coli purine nucleoside phosphorylase in tumor cells. The company is based in Birmingham, Alabama.

4363 1st Avenue North

Birmingham, AL 35222

United States





Key Executives for PNP Therapeutics, Inc.

Chief Executive Officer and Director
Co-Founder, President, Director and Member of Scientific Advisory Board
Co-Founder, Vice President, Secretary, Director and Member of Scientific Advisory Board
Compensation as of Fiscal Year 2015.

PNP Therapeutics, Inc. Key Developments

PNP Therapeutics Inc. Receives Orphan Drug Status for Gedeptin

PNP Therapeutics Inc. announced the Food and Drug Administration has granted orphan drug status to Gedeptin™, the company's lead product candidate (adenoviral vector expressing E. coli purine nucleoside phosphorylase gene) for the intratumoral treatment of anatomically accessible oral and pharyngeal cancers, including cancers of the lip, tongue, gum, floor of mouth, salivary gland and other oral cavities. The orphan drug designation is awarded to drugs designed to treat a rare disease or condition that affects fewer than 200,000 people in the U.S., and it is applied specifically to novel therapeutics that represent a major improvement. Orphan drug status provides regulatory incentives, reduced fees, and a more rapid review by the FDA, and stipulates that competing therapies can be blocked from the market for up to seven years. Additionally, this status qualifies the drug sponsor for various development incentives, including tax credits for qualified clinical testing.

PNP Therapeutics Provides Progress Update on Cancer-Fighting Technology in Phase I Clinical Trial

PNP Therapeutics, Inc. announced that it has found an approach that has abolished otherwise unmanageable human cancers in preclinical rodent studies. PNP confirmed that it has completed the first three cohorts of its Phase I clinical trial and is now recruiting for the fourth cohort. The company is looking ahead to Phase II trials and seeking an appropriate partner in the pharmaceutical industry. In Phase I clinical trials, patient safety and efficacy are evaluated. In PNP's Phase I trial, an adenoviral vector is used to deliver E. coli PNP to head and neck tumors followed by intravenous administration of the prodrug fludarabine. The therapy was well-tolerated in the first nine patients, and doctors have detected efficacy. The technology -- based on the notion that solid tumors can be programmed to generate their own very potent chemotherapy -- was discovered by Parker and Eric Sorscher, M.D., professor of Medicine of Hematology/Oncology at UAB. Selectivity of the therapeutic approach is achieved by producing an enzyme called E. coli purine nucleoside phosphorylase (PNP) directly within tumor cells and using the enzyme to generate novel chemotherapy in the tumor mass itself. The resulting compound works by a unique mechanism of action unlike any drug currently used in the treatment of cancer, and it destroys replicating and non replicating malignant cells while minimizing damage to surrounding, healthy cells.

Similar Private Companies By Industry

Company Name Region
ProZyme, Inc. United States
Millennium Predictive Medicine, Inc. United States
Centrillion Biosciences Inc. United States
Protherics Inc. United States
X-Ceptor Therapeutics, Inc. United States

Recent Private Companies Transactions

Private Placement
September 29, 2014

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PNP Therapeutics, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at